Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

- In Clinical Trial, Motavizumab Reduced Hospitalizations Due to

Respiratory Syncytial Virus by 83 Percent Compared to Placebo -

HONOLULU, May 4 /PRNewswire/ -- MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. Kate O'Brien, M.D., M.P.H., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, is the study's principal investigator. Aruna Chandran, M.D., M.P.H., a trial co-investigator, presents the data today at the Pediatric Academic Societies (PAS) Annual Meeting in Honolulu, HI.

This randomized Phase 3 study demonstrated that motavizumab reduced hospitalizations due to RSV by 83 percent as compared to placebo (8.3 percent in placebo arm versus 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

The randomized, double-blind Phase 3 study involving 1,410 full-term healthy infants less than six months of age in some Southwest Native American populations was designed to compare monthly intramuscular injections of motavizumab against placebo. In previous epidemiologic studies these populations were shown to have high rates of hospitalization due to RSV. This study confirmed the high rates of serious RSV disease in this population. An interim analysis, reviewed by an independent data safety monitoring committee, concluded there was statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 /PRNewswire/ ... needs of customers who are increasingly mobile, increasingly connected, ... support a growing variety of customer interaction channels and ... of technology, including social media. According ... of the over the counter (OTC) segment in a ...
(Date:7/31/2015)... July 31, 2015  Seeger Weiss LLP is reporting that ... a warning letter to C.R. Bard, the manufacturer of ... strides to correct violations the agency found at two of ... after the FDA cited them during Inspectional Observations that occurred ... Tempe, AZ , location and on October ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. ... an emerging leader in the development, assembly, marketing and ... announced that the Company will present at the CFA ... the Shanghai Purple Mountain Hotel in Shanghai on May ...
... May 17, 2012 Simbionix USA ... training and education products, is proud to announce ... the new GI Mentor™ Express simulator ... Mentor™ .      (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a) ...
Cached Medicine Technology:Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events 2
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... its new store run by GoodThreads. The store can be accessed by visiting ... designs, many of which are customizable. The best part: whenever a product is ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... an important workshop at its new True North Conference Center. The medical community, ... that the Jacksonville community may be more aligned in the effort to better ...
(Date:7/31/2015)... View, CA (PRWEB) , ... July 31, 2015 , ... ... for the athletes, judges, media, and VIPs at the 2015 Vans US Open of ... organic coconut water that can claim “no added sugar” on the market, is a ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... of Directors of WellPoint, Inc., has been appointed to its Board of Directors.   , ... , , ... ... "We are delighted to welcome Larry Glasscock to ...
... Tenn. , March 16 TeamHealth Holdings, Inc. ... suppliers of outsourced healthcare professional staffing and administrative services to ... , today announced that its management will be presenting at ... 24, 2010 , at the Loews Miami Hotel, Florida ...
... dangerous characteristics of cancer is its ability to metastasize, or ... major need for better tests to detect cells that break ... the body. Effective identification of these cells, referred to ... improve quality of life for many cancer patients. A commentary ...
... ... survey by Jackson Healthcare, 89 percent of physicians agree that patients receiving negligent treatment deserve ... Alpharetta, GA ... , 89 percent of physicians agree that patients receiving negligent treatment deserve fair compensation. , ...
... before surgery died soon after than those using ... -- In a trial comparing two anti-clotting drugs, patients ... to die than those given Plavix, researchers found. , ... but Plavix, the more popular drug, has been linked ...
... Lyons , President and CEO of the Elizabeth Glaser Pediatric AIDS Foundation: , ... , , ... ... The Elizabeth Glaser Pediatric AIDS ...
Cached Medicine News:Health News:Simon Property Group Elects Larry Glasscock to Board of Directors 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 3Health News:Revisiting the need to detect circulating tumor cells 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 2Health News:Recent Survey Reveals That Physicians Overwhelmingly Support Patient Compensation When Harmed 3Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 2Health News:Newer Blood Thinner Beats Plavix for Bypass Patients 3Health News:Elizabeth Glaser Pediatric AIDS Foundation President and CEO Charles Lyons Welcomes the Appointment of Anthony Lake as New Executive Director of UNICEF 2
... now recognized as an important intestinal ... Routine parasitological techniques fail to demonstrate ... techniques prove effective in staining this ... typical organisms on each slide. Each ...
... have a positive and negative inoculated well, ... these slides, perform QC and sample staining ... education and training programs by testing QC ... on one slide! KWIK-QC slides contain the ...
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Medicine Products: